| Ticker: UCOR | 800 Research Parkway | |
| Exchange: NASDAQ-National Market | Oklahoma City, Oklahoma 73104 | |
| Industry: Service | (405) 290-4000 |
| Type of Shares: | Common Shares | Filing Date: | 4/3/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 5/16/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $8.00 - $10.00 | |
| Primary Shares: | 0 | Offer Price: | $11.00 | |
| Secondary Shares: | 3,000,000 | Gross Spread: | $0.77 | |
| Offering Amount: | $27,000,000 | Selling: | $0.44 | |
| Expenses: | $600,000 | Reallowance: | $0.10 | |
| Shares Out After: | 9,565,248 |
| Manager | Tier | Phone |
| Montgomery Securities | Lead Manager | 4156272220 |
| Volpe, Welty & Company | Co-manager | (415) 956-8120 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $19.76 | $5.91 | $4.62 | Assets: | $12.03 |
| Net Income: | $0.53 | $0.23 | $0.09 | Liabilities: | $3.33 |
| EPS: | $0.07 | $0.03 | $0.01 | Equity: | $8.70 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company provides diagnostic services for the clinical management of certain urological cancers and diseases. The Company's goal is to complement its diagnostic services with therapeutic products and information systems in order to become the leading disease management company serving the urology market. Through its four business groups, UroDiagnostics, UroSciences, UroTherapeutics and Disease Management Information Systems, the Company is developing an integrated disease management approach to serve the needs of urologists and managed care organizations for the diagnostic, prognostic and therapeutic care of patients throughout a disease cycle. The UroDiagnostics Group provides diagnostic services to detect major urological diseases, predict prognosis of the disease. The UroSciences goal is to become the leader in the development and application of advanced diagnostic technologies and information resources for managing urological diseases. The UroTherapeutics Group was established to acquire rights to sell through the Company's existing sales force urological pharmaceutical products for use in the urologist's office. The Disease Management Information Systems group is designed to provide urologists and managed care organizations with access to the Company's proprietary urological disease database, disease management models and practice management guidelines in order to improve the diagnosis and treatment of patients. |
| Use of Proceeds |
| Proceeds from the offering will be used for development of new products, expansion of business lines, certain capital expenditures and working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.